Daclizumab
Daclizumab is a monoclonal antibodies that prevent T-lymphocytes proliferation. Daclizumab is used for prophylaxis of acute rejection in allogenic renal transplantation. Daclizumab is usually given in combination with ciclosporin and corticosteroid immunosuppression regimens.
Primary Characteristics
It is of Natural origin.
Molecular Weight: 142612.1 · Non-proprietary name: Daclizumab.
Pharmacokinetics
Elimination: plasma half-life is 20 days.
Advertisement
Indications
Daclizumab is primarily indicated in conditions like Metastatic.
Contraindications
Daclizumab is contraindicated in conditions like Pregnancy, Breast feeding.
Dosage
Daclizumab's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 1 mg/kg | 1 mg/kg | — | IV | Within 24 hrs before transplantation. Then every 14 days for a totalof 5 doses. |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
None recorded.
Side Effects
Daclizumab in overdosage may give rise to further complications which include Peripheral edema, Cardiac arrest , Anaphylactic reactions , Lymphoproliferative disorders, Respiratory failure, Laryngeal oedema.
Daclizumab is known to cause more or less tolerable side effects which are usually transient. These include Bronchospasm, Burnning sensation of hands, and feets, Fatigue, GI disturbance, Headache, Hypersensitivity reactions, Hypertension , Rashes , Tremor, Urticaria, Wheezing .
Warnings / Precautions
Available Brands
None recorded.
Drug Classification
- 1.8.2 — Cytotoxic (anti-neoplastic) drugs